{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:27:07Z","timestamp":1774686427064,"version":"3.50.1"},"reference-count":123,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8,1]]},"DOI":"10.1210\/jc.2008-1019","type":"journal-article","created":{"date-parts":[[2008,8,6]],"date-time":"2008-08-06T18:43:12Z","timestamp":1218048192000},"page":"2937-2945","source":"Crossref","is-referenced-by-count":36,"title":["Approach to the Human Immunodeficiency Virus-Infected Patient with Lipodystrophy"],"prefix":"10.1210","volume":"93","author":[{"given":"Todd T.","family":"Brown","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Johns Hopkins University, Baltimore, Maryland 21287"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041114012478800_R1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella Jr","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114012478800_R2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/505147","article-title":"The survival benefits of AIDS treatment in the United States.","volume":"194","author":"Walensky","year":"2006","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019041114012478800_R3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults.","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114012478800_R4","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.","volume":"19","author":"Dube","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","article-title":"Fat distribution in men with HIV infection.","volume":"40","author":"Bacchetti","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R6","first-page":"562","volume-title":"J Acquir Immune Defic Syndr","author":"Fat distribution in women with HIV infection","year":"2006"},{"key":"key\n\t\t\t\t2019041114012478800_R7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1086\/430379","article-title":"Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women.","volume":"40","author":"Jacobson","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041114012478800_R8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","article-title":"Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients.","volume":"32","author":"Lichtenstein","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00001432-200402000-00005","article-title":"What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection.","volume":"17","author":"Tien","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"key\n\t\t\t\t2019041114012478800_R10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy: prevalence, severity and correlates of risk in Australia.","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019041114012478800_R11","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1468-1293.2003.00151.x","article-title":"Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome.","volume":"4","author":"Kosmiski","year":"2003","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019041114012478800_R12","volume-title":"Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections","author":"Podzamczer","year":"2008"},{"key":"key\n\t\t\t\t2019041114012478800_R13","first-page":"1058","article-title":"Full scope of effect of facial lipoatrophy: a framework of disease understanding.","volume":"32","author":"Ascher","year":"2006","journal-title":"Dermatol Surg"},{"issue":"Suppl 4","key":"key\n\t\t\t\t2019041114012478800_R14","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/01.aids.0000191485.92285.c7","article-title":"Self-perception of body changes in persons living with HIV\/AIDS: prevalence and associated factors","volume":"19","author":"Santos","year":"2005","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00042560-200107010-00004","article-title":"Stavudine versus zidovudine and the development of lipodystrophy.","volume":"27","author":"Bogner","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/01.qai.0000224974.67962.ce","article-title":"Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals.","volume":"42","author":"Cherry","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R17","volume-title":"Program and Abstracts of the 14th Conference of Retroviruses and Opportunistic Infections","author":"Haubrich","year":"2007"},{"key":"key\n\t\t\t\t2019041114012478800_R18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/MLG.0b013e318064e8ab","article-title":"HIV-associated facial lipoatrophy: establishment of a validated grading scale.","volume":"117","author":"Funk","year":"2007","journal-title":"Laryngoscope"},{"key":"key\n\t\t\t\t2019041114012478800_R19","first-page":"979","article-title":"HIV-associated facial lipoatrophy.","volume":"28","author":"James","year":"2002","journal-title":"Dermatol Surg"},{"key":"key\n\t\t\t\t2019041114012478800_R20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/QAI.0b013e31815b0792","article-title":"Relation of body composition to body mass index in HIV-infected patients with metabolic abnormalities.","volume":"47","author":"Joy","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","article-title":"Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.","volume":"104","author":"Stein","year":"2001","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041114012478800_R23","first-page":"1045","article-title":"Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.","volume":"74","author":"Grunfeld","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114012478800_R24","author":"Hill","year":"2008"},{"key":"key\n\t\t\t\t2019041114012478800_R25","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1161\/01.ATV.20.12.2625","article-title":"HIV protease inhibitors stimulate hepatic triglyceride synthesis.","volume":"20","author":"Lenhard","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t2019041114012478800_R26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1468-1293.2005.00328.x","article-title":"The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations.","volume":"6","author":"Shafran","year":"2005","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019041114012478800_R27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041114012478800_R28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"19:354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114012478800_R29","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0010019","article-title":"Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1","volume":"1","author":"van Leth","year":"2004","journal-title":"PLoS Med [Erratum (2004) 1:e73]"},{"key":"key\n\t\t\t\t2019041114012478800_R30","first-page":"35","article-title":"Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women.","volume-title":"J Acquir Immune Defic Syndr","author":"Currier","year":"2008"},{"key":"key\n\t\t\t\t2019041114012478800_R31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/QAI.0b013e31816d9ba1","article-title":"The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men.","volume":"48","author":"Wohl","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1001\/archinte.165.10.1179","article-title":"Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study.","volume":"165","author":"Brown","year":"2005","journal-title":"Arch Int Med [Erratum (2005) 165:2541]"},{"key":"key\n\t\t\t\t2019041114012478800_R33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1086\/317541","article-title":"Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.","volume":"32","author":"Hadigan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041114012478800_R34","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00002030-200403050-00008","article-title":"The metabolic effects of lopinavir\/ritonavir in HIV-negative men.","volume":"18","author":"Lee","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R35","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200203290-00002","article-title":"Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study","volume":"16","author":"Noor","year":"2002","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R36","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1097\/00002030-200409030-00017","article-title":"Indinavir increases glucose production in healthy HIV-negative men.","volume":"18","author":"Schwartz","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R37","volume-title":"Program and Abstracts of the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV","author":"Lee","year":"2005"},{"key":"key\n\t\t\t\t2019041114012478800_R38","volume-title":"Program and Abstracts of the 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV","author":"Lee","year":"2004"},{"key":"key\n\t\t\t\t2019041114012478800_R39","doi-asserted-by":"crossref","first-page":"E1666","DOI":"10.1152\/ajpendo.00550.2006","article-title":"Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle in healthy adults","volume":"292","author":"Fleischman","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114012478800_R40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAD.0b013e3282f33557","article-title":"Zidovudine\/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.","volume":"22","author":"Blumer","year":"2008","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/QAI.0b013e31814b94e2","article-title":"Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study.","volume":"46","author":"Grunfeld","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R42","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00126334-200012010-00004","article-title":"Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy.","volume":"25","author":"Mynarcik","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R43","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/00002030-200009080-00008","article-title":"Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.","volume":"14","author":"Hatano","year":"2000","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R44","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment.","volume":"355","author":"El Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114012478800_R45","first-page":"459","article-title":"CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial.","volume-title":"Lancet","author":"Ananworanich","year":"2006"},{"key":"key\n\t\t\t\t2019041114012478800_R46","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1086\/343050","article-title":"Switching effective antiretroviral therapy: a review.","volume":"35","author":"Drechsler","year":"2002","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041114012478800_R47","first-page":"263","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.","volume-title":"Clin Infect Dis","author":"McComsey","year":"2004"},{"key":"key\n\t\t\t\t2019041114012478800_R48","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041114012478800_R49","volume-title":"Program and Abstracts of the 12th Conference of Retroviruses and Opportunistic Infections","author":"Moyle","year":"2005"},{"key":"key\n\t\t\t\t2019041114012478800_R50","volume-title":"Program and Abstracts of the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV","author":"da Silva","year":"2006"},{"key":"key\n\t\t\t\t2019041114012478800_R51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R52","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1310\/hct0806-381","article-title":"The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy.","volume":"8","author":"Valdez","year":"2007","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t2019041114012478800_R53","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114012478800_R54","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2310\/JIM.0b013e3181641b26","article-title":"Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir\/ritonavir.","volume":"56","author":"Busti","year":"2008","journal-title":"J Investig Med"},{"key":"key\n\t\t\t\t2019041114012478800_R55","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/317426","article-title":"Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.","volume":"31","author":"Martinez","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041114012478800_R56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00042560-200107010-00003","article-title":"Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.","volume":"27","author":"Ruiz","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R57","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200109280-00010","article-title":"HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.","volume":"15","author":"Carr","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R58","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/diabetes.50.6.1378","article-title":"The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.","volume":"50","author":"Caron","year":"2001","journal-title":"Diabetes"},{"key":"key\n\t\t\t\t2019041114012478800_R59","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-133-4-200008150-00009","article-title":"Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.","volume":"133","author":"Arioglu","year":"2000","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041114012478800_R60","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041114012478800_R61","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART-associated lipodystrophy\u2013a randomized double-blind placebo-controlled study.","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019041114012478800_R62","volume-title":"Program and Abstracts of the 13th Conference of Retroviruses and Opportunistic Infections","author":"Mulligan","year":"2006"},{"key":"key\n\t\t\t\t2019041114012478800_R63","doi-asserted-by":"crossref","first-page":"786","DOI":"10.7326\/0003-4819-140-10-200405180-00008","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.","volume":"140","author":"Hadigan","year":"2004","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041114012478800_R64","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/135965350801300107","article-title":"Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).","volume":"13","author":"Slama","year":"2008","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019041114012478800_R65","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1097\/01.aids.0000222072.37749.5a","article-title":"Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men\u2013a randomized, placebo-controlled study.","volume":"20","author":"Mallon","year":"2006","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R66","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/135965350300800514","article-title":"Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells.","volume":"8","author":"Walker","year":"2003","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019041114012478800_R67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/135965350701200113","article-title":"Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.","volume":"12","author":"Sutinen","year":"2007","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019041114012478800_R68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1468-1293.2006.00342.x","article-title":"Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.","volume":"7","author":"Moyle","year":"2006","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019041114012478800_R69","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/QAI.0b013e318158bec9","article-title":"A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy.","volume":"46","author":"Carey","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R70","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/QAD.0b013e3281c6148d","article-title":"Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.","volume":"21","author":"Loutfy","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R71","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1258\/095646207782193795","article-title":"Leisure time physical activity prevents accumulation of central fat in HIV\/AIDS subjects on highly active antiretroviral therapy.","volume":"18","author":"Florindo","year":"2007","journal-title":"Int J STD AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R72","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.metabol.2006.05.018","article-title":"Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women.","volume":"55","author":"Engelson","year":"2006","journal-title":"Metabolism"},{"key":"key\n\t\t\t\t2019041114012478800_R73","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/archinte.166.11.1225","article-title":"Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial.","volume":"166","author":"Dolan","year":"2006","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041114012478800_R74","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1249\/01.mss.0000191347.73848.80","article-title":"Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy.","volume":"38","author":"Terry","year":"2006","journal-title":"Med Sci Sports Exerc"},{"key":"key\n\t\t\t\t2019041114012478800_R75","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001796.pub2","article-title":"Aerobic exercise interventions for adults living with HIV\/AIDS","author":"Nixon","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019041114012478800_R76","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1210\/jc.2002-020709","article-title":"Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance.","volume":"87","author":"Hadigan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114012478800_R77","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/00002030-199905280-00023","article-title":"Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-143-5-200509060-00009","article-title":"Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.","volume":"143","author":"van Wijk","year":"2005","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041114012478800_R79","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1210\/jcem.86.2.7410","article-title":"Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.","volume":"86","author":"Hadigan","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114012478800_R80","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1210\/jc.2003-031858","article-title":"Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients.","volume":"89","author":"Driscoll","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114012478800_R81","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/QAD.0b013e328011220e","article-title":"Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist\/hip ratio.","volume":"21","author":"Mulligan","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R82","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1293.2007.00488.x","article-title":"A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy.","volume":"8","author":"Kohli","year":"2007","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019041114012478800_R83","volume-title":"Program and Abstracts of the 13th Conference of Retroviruses and Opportunistic Infections","author":"Kohli","year":"2006"},{"key":"key\n\t\t\t\t2019041114012478800_R84","first-page":"504","article-title":"Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.","volume":"86","author":"Rietschel","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114012478800_R85","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1210\/jc.2004-1342","article-title":"Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy.","volume":"90","author":"Koutkia","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114012478800_R86","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.292.2.210","article-title":"Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.","volume":"292","author":"Koutkia","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041114012478800_R87","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMoa072375","article-title":"Metabolic effects of a growth hormone-releasing factor in patients with HIV.","volume":"357","author":"Falutz","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114012478800_R88","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1468-1293.2006.00399.x","article-title":"A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy.","volume":"7","author":"Bickel","year":"2006","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019041114012478800_R89","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/ajcn\/84.1.204","article-title":"Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome.","volume":"84","author":"D'Amico","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"key\n\t\t\t\t2019041114012478800_R90","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00042560-200208010-00002","article-title":"Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.","volume":"30","author":"Engelson","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R91","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/QAI.0b013e31804a7f68","article-title":"Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy.","volume":"45","author":"Grunfeld","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R92","volume-title":"Program and Abstracts of the 15th Conference of Retroviruses and Opportunistic Infections","author":"Lo","year":"2008"},{"key":"key\n\t\t\t\t2019041114012478800_R93","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1210\/jcem.86.8.7785","article-title":"The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.","volume":"86","author":"Lo","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114012478800_R94","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/00002030-199910220-00013","article-title":"Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV.","volume":"13","author":"Wanke","year":"1999","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R95","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.sap.0000248128.33465.83","article-title":"Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy.","volume":"58","author":"Hultman","year":"2007","journal-title":"Ann Plast Surg"},{"key":"key\n\t\t\t\t2019041114012478800_R96","first-page":"3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume-title":"Circulation","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002"},{"key":"key\n\t\t\t\t2019041114012478800_R97","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1468-1293.2007.00534.x","article-title":"European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.","volume":"9","author":"Lundgren","year":"2008","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019041114012478800_R98","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","article-title":"Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group.","volume":"37","author":"Dube\u0301","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041114012478800_R99","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1468-1293.2006.00362.x","article-title":"The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.","volume":"7","author":"Law","year":"2006","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t2019041114012478800_R100","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2165\/00003088-200241140-00004","article-title":"Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.","volume":"41","author":"Fichtenbaum","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019041114012478800_R101","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/00002030-200203080-00008","article-title":"Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.","volume":"16","author":"Fichtenbaum","year":"2002","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R102","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/QAI.0b013e318160a542","article-title":"Drug\/drug interaction between lopinavir\/ritonavir and rosuvastatin in healthy volunteers.","volume":"47","author":"Kiser","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R103","first-page":"307","article-title":"Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study","volume-title":"J Acquir Immune Defic Syndr","author":"Gerber","year":"5108"},{"key":"key\n\t\t\t\t2019041114012478800_R104","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/apc.2007.0206","article-title":"Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.","volume":"22","author":"Berg-Wolf","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"key\n\t\t\t\t2019041114012478800_R105","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/01.aids.0000238418.43937.3b","article-title":"Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.","volume":"20","author":"Coll","year":"2006","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041114012478800_R106","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s15010-001-2052-3","article-title":"Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.","volume":"30","author":"Calza","year":"2002","journal-title":"Infection"},{"key":"key\n\t\t\t\t2019041114012478800_R107","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00000441-200406000-00003","article-title":"Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy.","volume":"327","author":"Rao","year":"2004","journal-title":"Am J Med Sci"},{"key":"key\n\t\t\t\t2019041114012478800_R108","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/QAI.0b013e31802c2f3d","article-title":"Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study.","volume":"44","author":"De Truchis","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R109","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/497273","article-title":"Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.","volume":"41","author":"Wohl","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041114012478800_R110","volume-title":"Program and Abstracts of the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV","author":"Dube","year":"2005"},{"key":"key\n\t\t\t\t2019041114012478800_R111","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1089\/aid.2005.21.757","article-title":"A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087","volume":"21","author":"Aberg","year":"2005","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t2019041114012478800_R112","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.","volume":"29","author":"Nathan","year":"2006","journal-title":"Diabetes Care [Erratum (2006) 49:2816\u20132818]"},{"key":"key\n\t\t\t\t2019041114012478800_R113","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2337\/diacare.28.7.1547","article-title":"A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.","volume":"28","author":"Goldberg","year":"2005","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019041114012478800_R114","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041114012478800_R115","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114012478800_R116","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2337\/dc07-9920","article-title":"Impaired fasting glucose and impaired glucose tolerance: implications for care.","volume":"30","author":"Nathan","year":"2007","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t2019041114012478800_R117","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1210\/jc.2006-2190","article-title":"Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease.","volume":"92","author":"Triant","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041114012478800_R118","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction.","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114012478800_R119","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.","volume":"348","author":"Bozzette","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041114012478800_R120","volume-title":"Program and Abstracts of the 13th Conference of Retroviruses and Opportunistic Infections","author":"Lichtenstein","year":"2006"},{"key":"key\n\t\t\t\t2019041114012478800_R121","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0b013e318157131c","article-title":"Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.","volume":"46","author":"Markowitz","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041114012478800_R122","volume-title":"Program and Abstracts of the 15th Conference of Retroviruses and Opportunistic Infections","author":"DeJesus","year":"2008"},{"key":"key\n\t\t\t\t2019041114012478800_R123","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.","volume":"371","author":"D:A:D Study Group, Sabin","year":"2008","journal-title":"Lancet"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/8\/2937\/9051825\/jcem2937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T02:40:16Z","timestamp":1709174416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/8\/2937\/2598238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":123,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-1019","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}